PMID- 38024636 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231201 IS - 2688-6146 (Electronic) IS - 2688-6146 (Linking) VI - 4 IP - 4 DP - 2023 Nov TI - PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma. PG - 1081-1088 LID - 10.1002/jha2.757 [doi] AB - Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment option for relapsed or refractory (R/R) large B-cell lymphoma (LBCL). However, only a subset of patients will present long-term benefit. In this study, we explored the potential of PET-based radiomics to predict treatment outcomes with the aim of improving patient selection for CAR T-cell therapy. We conducted a single-center study including 93 consecutive R/R LBCL patients who received a CAR T-cell infusion from 2018 to 2021, split in training set (73 patients) and test set (20 patients). Radiomics features were extracted from baseline PET scans and clinical benefit was defined based on median progression-free survival (PFS). Cox regression models including the radiomics signature, conventional PET biomarkers and clinical variables were performed for most relevant outcomes. A radiomics signature including 4 PET-based parameters achieved an AUC = 0.73 for predicting clinical benefit in the test set, outperforming the predictive value of conventional PET biomarkers (total metabolic tumor volume [TMTV]: AUC = 0.66 and maximum standardized uptake value [SUV(max)]: AUC = 0.59). A high radiomics score was also associated with longer PFS and OS in the multivariable analysis. In conclusion, the PET-based radiomics signature predicted efficacy of CAR T-cell therapy and outperformed conventional PET biomarkers in our cohort of LBCL patients. CI - (c) 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. FAU - Ligero, Marta AU - Ligero M AUID- ORCID: 0000-0001-9824-7316 AD - Radiomics Group Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus (VHUH) Barcelona Spain. FAU - Simo, Marc AU - Simo M AD - Nuclear Medicine Department Vall d'Hebron University Hospital, Autonomous University of Barcelona Barcelona Spain. FAU - Carpio, Cecilia AU - Carpio C AUID- ORCID: 0000-0001-9346-0134 AD - Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain. FAU - Iacoboni, Gloria AU - Iacoboni G AD - Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain. FAU - Balaguer-Montero, Maria AU - Balaguer-Montero M AD - Radiomics Group Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus (VHUH) Barcelona Spain. FAU - Navarro, Victor AU - Navarro V AD - Oncology Data Science (ODysSey) Group Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain. FAU - Sanchez-Salinas, Mario Andres AU - Sanchez-Salinas MA AD - Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain. FAU - Bobillo, Sabela AU - Bobillo S AD - Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain. FAU - Marin-Niebla, Ana AU - Marin-Niebla A AD - Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain. FAU - Iraola-Truchuelo, Josu AU - Iraola-Truchuelo J AD - Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain. FAU - Abrisqueta, Pau AU - Abrisqueta P AD - Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain. FAU - Sala-Llonch, Roser AU - Sala-Llonch R AD - Faculty of Medicine Department of Biomedicine Institute of Neurosciences, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) University of Barcelona Barcelona Spain. AD - Centro de Investigacion Biomedica en Red de Bioingenieria Biomateriales y Nanomedicina (CIBER-BBN) Barcelona Spain. FAU - Bosch, Francesc AU - Bosch F AD - Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain. FAU - Perez-Lopez, Raquel AU - Perez-Lopez R AUID- ORCID: 0000-0002-9176-0130 AD - Radiomics Group Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus (VHUH) Barcelona Spain. FAU - Barba, Pere AU - Barba P AD - Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain. LA - eng PT - Journal Article DEP - 20230911 PL - United States TA - EJHaem JT - EJHaem JID - 101761942 PMC - PMC10660117 OTO - NOTNLM OT - CAR T cells OT - DLBCL OT - PET OT - non-Hodgkin lymphoma OT - progression-free survival OT - radiomics COIS- PB receives honoraria from Allogene, Amgen, BMS, Gilead, Miltenyi Biomedicine, Pierre Fabre, Nektar, Novartis, and Pfizer. GI receives consultancy and honoraria from Novartis, Roche, Kite/Gilead, Bristol-Myers Squibb, Abbvie, Janssen, Sandoz, Miltenyi, and AstraZeneca. SB receives honoraria from AstraZeneca, ROCHE, Janssen, and Abbvie. This work was partially presented at the 64th Annual Meeting of the American Society of Hematology, 2022. EDAT- 2023/11/29 18:42 MHDA- 2023/11/29 18:43 PMCR- 2023/09/11 CRDT- 2023/11/29 16:13 PHST- 2023/06/07 00:00 [received] PHST- 2023/07/05 00:00 [revised] PHST- 2023/07/14 00:00 [accepted] PHST- 2023/11/29 18:43 [medline] PHST- 2023/11/29 18:42 [pubmed] PHST- 2023/11/29 16:13 [entrez] PHST- 2023/09/11 00:00 [pmc-release] AID - JHA2757 [pii] AID - 10.1002/jha2.757 [doi] PST - epublish SO - EJHaem. 2023 Sep 11;4(4):1081-1088. doi: 10.1002/jha2.757. eCollection 2023 Nov.